VERTEX PHARMACEUTICALS INC / MA Payments To Acquire Equity Securities Fv Ni
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Payments To Acquire Equity Securities Fv Ni of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquitySecuritiesFvNi · last filed 2024-05-07
- VERTEX PHARMACEUTICALS INC / MA payments to acquire equity securities fv ni for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire equity securities fv ni for the quarter ending 2023-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire equity securities fv ni for the quarter ending 2023-09-30 was $1.10M, a 97.09% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire equity securities fv ni for the quarter ending 2023-06-30 was $5.00M, a 50.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire equity securities fv ni for fiscal 2023 was $31.00M, a 35.15% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire equity securities fv ni for fiscal 2022 was $47.80M, a 37.92% decline from fiscal 2021.
- VERTEX PHARMACEUTICALS INC / MA payments to acquire equity securities fv ni for fiscal 2021 was $77.00M.
| Period end | Payments To Acquire Equity Securities Fv Ni 3 month | Payments To Acquire Equity Securities Fv Ni 6 month | Payments To Acquire Equity Securities Fv Ni 9 month | Payments To Acquire Equity Securities Fv Ni 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2024-05-07 | $1.10M derived: sum of 3 quarters · filed 2024-05-07 | $6.10M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.10M derived: sum of 2 quarters · filed 2024-02-15 | $6.10M derived: sum of 3 quarters · filed 2024-02-15 | $31.00M 10-K · filed 2024-02-15 |
| 2023-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $6.10M derived: sum of 2 quarters · filed 2023-11-07 | $31.00M 10-Q · filed 2023-11-07 | $31.00M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $29.90M 10-Q · filed 2023-08-02 | $29.90M derived: sum of 3 quarters · filed 2024-05-07 | $67.70M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-03-31 | $24.90M 10-Q · filed 2024-05-07 | $24.90M derived: sum of 2 quarters · filed 2024-05-07 | $62.70M derived: sum of 3 quarters · filed 2024-05-07 | $72.70M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $37.80M derived: sum of 2 quarters · filed 2024-02-15 | $47.80M derived: sum of 3 quarters · filed 2024-02-15 | $47.80M 10-K · filed 2024-02-15 |
| 2022-09-30 | $37.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $47.80M derived: sum of 2 quarters · filed 2023-11-07 | $47.80M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $10.00M 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | $77.00M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |